The effect of the administration of human gamma globulins in a model of BCG infection in mice

Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection

“…In one work, granulomes from lungs of human gammaglobulin-treated mice were morphologically similar to those developed by BCG-vaccinated mice (Acosta et al, 1994). Moreover, in a model of intranasal challenge with BCG in mice, the human gammaglobulin showed protective activity (Olivares et al, 2006). Taking into account the complex epidemiological situation of tuberculosis worldwide and the evidences accumulated up today regarding humoral immunity against mycobacterial infections, we consider of great importance to study the potential use of antibody formulations in the modulation of immune response and activation of effective mechanisms to control the progression of the disease.…”

Towards a New Challenge in TB Control: Development of Antibody-Based Protection

“…This treatment inhibited BCG colonization of the lungs of treated mice. A similar inhibitory effect was observed after infection of mice with gammaglobulin-opsonized BCG [42]. The same formulation was evaluated also in a mouse model of intratracheal infection with M. tuberculosis.…”

Role of B Cells and Antibodies in Acquired Immunity against Mycobacterium tuberculosis

“…Evidence that passive Ab transfer can improve the outcome of experimental mycobacterial infection in mice was documented by eight independent groups for mAbs against mycobacterial Ags (Teitelbaum et al 1998;Pethe et al 2001;Chambers et al 2004;Hamasur et al 2004;Williams et al 2004;Buccheri et al 2009;Lopez et al 2009;Balu et al 2011) and three recent studies with polyclonal IgG or serum within the same species (mice) or from humans to mice (Roy et al 2005;Guirado et al 2006;Olivares et al 2006) (Table 2). Studies that have probed the role of protective mAbs have used a variety of parameters to assess their efficacy including prolongation in survival time (Teitelbaum et al 1998;Chambers et al 2004;Hamasur et al 2004), reduced dissemination (Pethe et al 2001), reduced tissue pathology Lopez et al 2009;Balu et al 2011), and reduced mycobacterial burden as measured by colony forming units (CFU) (Hamasur et al 2004;Williams et al 2004;Buccheri et al 2009;Lopez et al 2009;Balu et al 2011).…”

“…Although a significant reduction of lung CFU was seen with the combination of mAb and IFN-g, and a borderline effect for mAb alone, no significant CFU reduction was seen with IFN-g alone, pointing toward a potentially important interplay between Ab and cytokine in the protection against TB. Recent passive Ab transfer studies in mice using homologous or heterologous (human) sera have also shown protection against experimental infection (Roy et al 2005;Guirado et al 2006;Olivares et al 2006). However, none of these monoclonal or polyclonal Ab transfer studies include a comparison to the efficacy of BCG (Bacille Calmette-Guérin) vaccination in mice.…”

“…Three independent groups have recently shown protection in mice with passive transfer of immune polyclonal sera. Teitelbaum et al 1998;Pethe et al 2001;Chambers et al 2004;Hamasur et al 2004;Williams et al 2004;Buccheri et al 2009;Lopez et al 2009;Balu et al 2011Roy et al 2005Guirado et al 2006;Olivares et al 2006 High Ab titer associated with reduced susceptibility Beyazova et al 1995;Cruz and Starke 2007;Donald et al 2010Sada et al 1990Costello et al 1992;Boggian et al 1996;Gupta et al 1997;Dayal et al 2008Kunnath-Velayudhan et al 2012Vordermeier et al 1996Maglione et al 2007Tjarnlund et al 2006Rodriguez et al 2005 4057 (IgG3) HBHA ( es variable reduction in CFU at 30 d of infection (Keyser et al 2011), the effects of passive mAb varied from being less than, comparable, and greater than described for BCG vaccines (reviewed in Achkar and Casadevall 2013). Additional transfer studies with more standardized designs, and ideally an additional BCG-vaccinated control group, are needed to allow for better comparison of the effects of Ab-based protection against Mtb.…”